Aileron Therapeutics is a biopharmaceutical company that develops and commercializes stabilized cell-permeating alpha-helical peptides to address intracellular targets in oncology and other therapeutic areas. The company's product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53's interactions with its endogenous inhibitors, MDMX and MDM2. ALRN-6924 is designed to activate the mechanisms used by p53 in cells with non-mutant, or wild-type, p53 to regulate cell division and progression through the cell replication cycle, programmed death of cancerous cells, or apoptosis, and induction of the immune system to respond against cancer cells.

Akcea Therapeutics is biopharmaceutical company developing and marketing drugs globally to treat patients with rare and serious diseases. The company's TEGSEDI treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. The company is also focused on commercial preparations for WAYLIVRA in the European Union. WAYLIVRA is an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome, who are at risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. TEGSEDI, WAYLIVRA and its pipeline drugs are based on the company's antisense technology platform.

Entercom Communications is a holding company. Through its subsidiaries, Co, is a media and entertainment company primarily engaged in the sale of advertising time to local, regional and national advertisers and national network advertisers who purchase commercials in varying lengths. The company focuses on station-related digital product suites, which allow for audience interaction and participation, and integrated digital advertising solutions. The company's stations are classified by their format, such as news, sports, talk, classic rock, urban, adult contemporary, alternative and country, among others.

Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines to treat, cure, and protect people from diseases associated with human papillomavirus, cancer, and infectious diseases. The company's DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies. The company's DNA medicine candidates are made using its proprietary SynCon? technology that creates plasmids, which are circular strands of DNA that can produce antigens inside a cell to help the person's immune system recognize and destroy cancerous or infected cells.

IntriCon is is an international company engaged in designing, developing, engineering and manufacturing miniature interventional, implantable and body-worn medical devices. The company serves as a joint development manufacturing partner to medical device original equipment manufacturers by designing, developing, engineering, manufacturing and distributing micro-miniature products, microelectronics, micro-mechanical assemblies, assemblies and software solutions, primarily for markets, such as diabetes, drug delivery, surgical navigation, and hearing health.

MMA Capital Holdings invests in debt associated with renewable energy infrastructure and real estate. The company's assets and liabilities are organized into two portfolios: Energy Capital, which this portfolio consists primarily of investments that the company has made through joint ventures with an institutional capital partner in loans that finance renewable energy projects; and Other Assets and Liabilities, which this portfolio includes the company's investments in bonds and related financing, certain loan receivables, cash, real estate-related investments, subordinated debt and the balance of its assets and liabilities.

PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The company's tissue product, SkinTE is registered with the United States Food and Drug Administration, and is commercially available for the repair, reconstruction, replacement and regeneration of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts.

SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.

Vermillion is engaged in the discovery, development and commercialization of diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women. The company concentrates its development of diagnostic tests for gynecologic disease, with an initial focus on ovarian cancer. The company's primary product, OVA1, is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian tumor prior to planned surgery. The company's ASPiRA LABS engages in applying biomarker-based technologies to address needs in the management of gynecologic cancers and disease.